Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 248,254,624
  • Shares Outstanding, K 3,100,470
  • Annual Sales, $ 45,811 M
  • Annual Income, $ 5,955 M
  • 60-Month Beta 0.48
  • Price/Sales 5.36
  • Price/Cash Flow 14.68
  • Price/Book 6.55
Trade AZN with:

Options Overview Details

View History
  • Implied Volatility 18.51% ( -0.75%)
  • Historical Volatility 15.87%
  • IV Percentile 5%
  • IV Rank 17.76%
  • IV High 31.19% on 10/16/23
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 0.82
  • Today's Volume 3,981
  • Volume Avg (30-Day) 6,313
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 126,072
  • Open Int (30-Day) 139,429

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.98
  • Number of Estimates 5
  • High Estimate 1.07
  • Low Estimate 0.89
  • Prior Year 1.08
  • Growth Rate Est. (year over year) -9.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.79 +4.93%
on 05/29/24
80.86 -1.64%
on 06/06/24
+2.10 (+2.71%)
since 05/13/24
3-Month
65.20 +21.98%
on 03/20/24
80.86 -1.64%
on 06/06/24
+11.95 (+17.68%)
since 03/13/24
52-Week
60.47 +31.52%
on 02/12/24
80.86 -1.64%
on 06/06/24
+5.40 (+7.28%)
since 06/13/23

Most Recent Stories

More News
Is Pfizer Stock Underperforming the Nasdaq?

Pfizer has recently lagged the Nasdaq Composite, but analysts are optimistic about the stock’s prospects.

PFE : 27.65 (-0.04%)
$NASX : 17,667.56 (+0.34%)
AZN : 79.53 (-0.67%)
1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer...

AZN : 79.53 (-0.67%)
DSNKY : 35.4500 (-1.53%)
MS : 95.21 (-0.46%)
PFE : 27.65 (-0.04%)
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.

There's probably a big enough pie here for everyone to get a slice.

LLY : 883.33 (+1.85%)
AMGN : 298.50 (-0.86%)
AZN : 79.53 (-0.67%)
VKTX : 52.10 (-0.69%)
3 No-Brainer Stocks to Buy in June

Now is the time to invest in these great stocks.

ABBV : 166.56 (+0.28%)
AZN : 79.53 (-0.67%)
VRTX : 479.03 (+0.68%)
This Pharma Stock Is Poised to Keep Outperforming the S&P 500

AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years.

AZN : 79.53 (-0.67%)
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock

Both businesses have road maps for the future, but one is better.

PFE : 27.65 (-0.04%)
AZN : 79.53 (-0.67%)
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?

Its new strategic roadmap aims to catapult the company forward.

AZN : 79.53 (-0.67%)
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

ONCY : 1.0300 (unch)
CADL : 7.54 (-0.53%)
AZN : 79.53 (-0.67%)
MRUS : 57.65 (+1.75%)
LTRN : 5.44 (-3.72%)
ONC.TO : 1.40 (-3.45%)
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according...

ONCY : 1.0300 (unch)
ONC.TO : 1.40 (-3.45%)
CADL : 7.54 (-0.53%)
AZN : 79.53 (-0.67%)
MRUS : 57.65 (+1.75%)
LTRN : 5.44 (-3.72%)
Stocks Finish Higher Ahead of Nvidia’s Earnings

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.21%. US stock indexes...

$SPX : 5,433.74 (+0.23%)
SPY : 542.45 (+0.20%)
$DOWI : 38,647.10 (-0.17%)
DIA : 386.88 (-0.21%)
$IUXX : 19,576.92 (+0.57%)
QQQ : 476.72 (+0.54%)
^ETHUSD : 3,506.567 (+0.87%)
ZNU24 : 110-150 (-0.23%)
DLTR : 106.53 (-2.15%)
M : 19.01 (-1.30%)
LLY : 883.33 (+1.85%)
AZN : 79.53 (-0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 80.51
2nd Resistance Point 80.06
1st Resistance Point 79.80
Last Price 79.53
1st Support Level 79.09
2nd Support Level 78.64
3rd Support Level 78.38

See More

52-Week High 80.86
Last Price 79.53
Fibonacci 61.8% 73.07
Fibonacci 50% 70.67
Fibonacci 38.2% 68.26
52-Week Low 60.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar